美股市場個股詳情
IPHA Innate Pharma
- 2.400
- -0.030-1.23%
交易中 05/03 10:33 (美東)
1.94億總市值-24742市盈率TTM
2.420最高價2.400最低價3706股成交量2.420今開2.430昨收8906.93成交額0.01%換手率虧損市盈率(靜)8084.20萬總股本3.57052周最高3.48市淨率1.30億流通值1.81052周最低--股息TTM5434.74萬流通股11.950歷史最高--股息率TTM0.82%振幅1.810歷史最低2.403平均價1股每手
關於Innate Pharma公司
Innate Pharma SA是一家處於臨牀試驗階段的生物技術公司，致力於開發針對癌症患者的免疫治療藥物。其方法是通過治療性抗體和專有平臺ANKET（基於抗體的NK細胞接合療法）來利用先天免疫系統。公司的收入來自於與製藥公司簽訂的研究、合作和許可協議所獲得的款項。其產品管線包括lacutamab、monalizumab、IPH5201、IPH5301、IPH6101、IPH62、IPH6401和IPH6501。
公司介紹
公司代碼IPHA
公司名稱Innate Pharma
上市日期2019/10/17
發行價格5.50
成立日期1999
CEODr. Mondher Mahjoubi, M.D.
所屬市場納斯達克
員工數量179
證券類型存託憑證（普通股）
ADS轉換比例1.0 : 1.0
年結日12-31
公司地址117, Avenue de Luminy
城市Marseille
省份普羅旺斯-阿爾卑斯-藍色海岸
國家法國
郵編13009
電話33-4-30-30-30-30
董事高管
- 姓名
- 職務
- 年薪
- Dr. Mondher Mahjoubi, M.D.
- Chairman of the Executive Board and Chief Executive Officer
- 149.14萬
- Eric Vivier, PhD
- Senior Vice President and Chief Scientific Officer
- --
- Sonia Quaratino
- Chief Medical Officer and Executive Vice President
- --
- Frederic Lombard
- Chief Financial Officer
- --
- Nicola Beltraminelli
- Vice President and Chief Development Officer
- --
- Yannis Morel, PhD
- Member of the Executive Board and Executive Vice President, Product Portfolio Strategy and Business Development
- 63.78萬
- Claire de Saint Blanquat
- Vice President, Legal and Corporate Affairs
- --
- Odile Laurent
- Vice President, Human Resources
- --
- Odile Belzunce
- Vice President, Compliance, IT and Portfolio Management
- --
- Henry Wheeler
- Vice President, Investor Relations and Communications
- --
- Herve Brailly, PhD
- Chairman of the Supervisory Board
- --
- Irina Staatz-Granzer, PhD
- Vice Chairman of the Supervisory Board
- 4.01萬
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅